WNT Stock Overview
A biotech company, develops therapies to prevent the metastatic process. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
WntResearch AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.69 |
| 52 Week High | SEK 17.20 |
| 52 Week Low | SEK 0.60 |
| Beta | 0.56 |
| 11 Month Change | -16.87% |
| 3 Month Change | -94.91% |
| 1 Year Change | -92.74% |
| 33 Year Change | -98.67% |
| 5 Year Change | -99.91% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| WNT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -4.4% | -5.8% | -2.1% |
| 1Y | -92.7% | 14.3% | 10.8% |
Return vs Industry: WNT underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: WNT underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| WNT volatility | |
|---|---|
| WNT Average Weekly Movement | 30.4% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: WNT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: WNT's weekly volatility has increased from 23% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2 | Per Goran Norlen | www.wntresearch.com |
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer.
WntResearch AB Fundamentals Summary
| WNT fundamental statistics | |
|---|---|
| Market cap | SEK 5.98m |
| Earnings (TTM) | -SEK 41.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs WNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WNT income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 41.00m |
| Earnings | -SEK 41.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did WNT perform over the long term?
See historical performance and comparison